What is HC Wainwright's Forecast for MLTX FY2025 Earnings?

Key Points

• HC Wainwright has raised its FY2025 earnings per share estimate for MoonLake Immunotherapeutics to ($3.29) from a previous estimate of ($3.37), maintaining a "Neutral" rating on the stock.
• The current consensus estimate for the company’s full-year earnings is significantly higher at ($1.79) per share, indicating differing outlooks among analysts.
• Recent insider trading reports show major shareholder Bihua Chen sold 6.5 million shares for over $46 million, reducing their ownership substantially, which may raise concerns among investors.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Equities research analysts at HC Wainwright upped their FY2025 earnings per share estimates for MoonLake Immunotherapeutics in a report released on Thursday, October 2nd. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($3.29) per share for the year, up from their prior estimate of ($3.37). HC Wainwright has a "Neutral" rating on the stock. The consensus estimate for MoonLake Immunotherapeutics' current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for MoonLake Immunotherapeutics' Q4 2025 earnings at ($0.80) EPS, Q1 2026 earnings at ($0.70) EPS, Q2 2026 earnings at ($0.70) EPS, Q3 2026 earnings at ($0.69) EPS, Q4 2026 earnings at ($0.67) EPS and FY2026 earnings at ($2.77) EPS.

MLTX has been the subject of a number of other research reports. Wolfe Research cut shares of MoonLake Immunotherapeutics from an "outperform" rating to an "underperform" rating in a research note on Tuesday, September 30th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $7.00 target price on shares of MoonLake Immunotherapeutics in a research note on Wednesday, October 1st. Weiss Ratings reiterated a "sell (d-)" rating on shares of MoonLake Immunotherapeutics in a research note on Saturday, September 27th. BTIG Research cut shares of MoonLake Immunotherapeutics from a "buy" rating to a "neutral" rating and set a $85.00 target price for the company. in a research note on Monday, September 29th. Finally, Redburn Atlantic upgraded shares of MoonLake Immunotherapeutics to a "hold" rating in a research note on Monday, July 28th. Three investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $37.00.

MoonLake Immunotherapeutics Stock Performance

NASDAQ:MLTX opened at $8.43 on Monday. MoonLake Immunotherapeutics has a 1 year low of $5.95 and a 1 year high of $62.75. The firm has a 50 day moving average of $49.95 and a 200-day moving average of $45.11. The company has a current ratio of 16.65, a quick ratio of 16.65 and a debt-to-equity ratio of 0.21. The stock has a market capitalization of $541.47 million, a P/E ratio of -3.03 and a beta of 1.10.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.87) earnings per share for the quarter, missing analysts' consensus estimates of ($0.73) by ($0.14). During the same quarter in the prior year, the business earned ($0.39) earnings per share.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Westfield Capital Management Co. LP grew its holdings in shares of MoonLake Immunotherapeutics by 9.4% in the 1st quarter. Westfield Capital Management Co. LP now owns 1,434,770 shares of the company's stock valued at $56,056,000 after buying an additional 123,151 shares during the period. Alliancebernstein L.P. boosted its stake in MoonLake Immunotherapeutics by 17.8% in the 2nd quarter. Alliancebernstein L.P. now owns 1,138,022 shares of the company's stock worth $53,715,000 after purchasing an additional 171,932 shares during the period. Hood River Capital Management LLC boosted its stake in MoonLake Immunotherapeutics by 1.9% in the 2nd quarter. Hood River Capital Management LLC now owns 675,445 shares of the company's stock worth $31,881,000 after purchasing an additional 12,462 shares during the period. Nuveen LLC acquired a new position in MoonLake Immunotherapeutics in the 1st quarter worth $26,308,000. Finally, Vestal Point Capital LP boosted its stake in MoonLake Immunotherapeutics by 175.0% in the 2nd quarter. Vestal Point Capital LP now owns 550,000 shares of the company's stock worth $25,960,000 after purchasing an additional 350,000 shares during the period. Institutional investors and hedge funds own 93.85% of the company's stock.

Insider Activity

In other news, major shareholder Bihua Chen sold 6,494,151 shares of the business's stock in a transaction on Monday, September 29th. The shares were sold at an average price of $7.21, for a total value of $46,822,828.71. Following the completion of the transaction, the insider owned 2,000,000 shares of the company's stock, valued at $14,420,000. The trade was a 76.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 12.02% of the stock is owned by company insiders.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.